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Protein phosphatase 2A- (PP2A-) catalyzed dephosphorylation of target substrate proteins is widespread and critical for cellular
function. PP2A is predominantly found as a heterotrimeric complex of a catalytic subunit (C), a scaﬀolding subunit (A), and one
member of 4 families of regulatory subunits (B). Substrate speciﬁcity of the holoenzyme complex is determined by the subcellular
locale the complex is conﬁned to, selective incorporation of the B subunit, interactions with endogenous inhibitory proteins, and
speciﬁc intermolecular interactions between PP2A and target substrates. Here, we discuss recent studies that have advanced our
understanding of the molecular determinants for PP2A substrate speciﬁcity.
1.Introduction
Cellular adaptation requires biochemical processes including
post-translational mechanisms to modify existing proteins.
Catalyzed by opposing kinases and phosphatases, reversible
phosphorylation of serine, threonine, and tyrosine residues
is now appreciated as a fundamental regulatory mechanism
with the majority of phosphorylation (>99%) occurring
on serine and threonine residues [1, 2]. Due to their
untapped therapeutic potential, protein phosphatases have
been identiﬁed as promising targets for xenobiotic manipu-
lation through rational drug design (reviewed in [3–6]). In
particular, the ubiquitously expressed protein phosphatase
2A (PP2A) has been proposed as a target for the treatment
of a number of pathologies ranging from neurodegenerative
diseases such as Alzheimer disease to a variety of neoplasias
[7–9].
Compared to other members of the phosphoprotein
phosphatase (PPP) superfamily of serine/threonine phos-
phatases, a detailed understanding of the mechanism by
which PP2A recognizes substrates and mediates site-speciﬁc
dephosphorylation remains to be developed. Sequence and
structural homology of the catalytic subunits of PPP family
members has revealed a conserved catalytic mechanism in
which a divalent metal cation activates a water molecule to
hydrolyze phospho-serine/threonine without the formation
of a phosphoenzyme intermediate (reviewed in [10–12]).
Despite a shared catalytic mechanism, substrate speciﬁcity
within the PPP family is mediated by distinct mechanisms
of substrate recognition. For example, the PPP calcineurin
(also known as protein phosphatase 2B) has been shown
to interact with two consensus sequences, PxIxIT and
LxVP, found on nonsubstrate-interacting proteins and target
substrates (reviewed in [11, 13]). For protein phosphatase-1
(PP1), substrate speciﬁcity is conferred by incorporation of
PP1-interacting proteins via a conserved docking motif with
a general consensus sequence of RVxF (reviewed in [11, 12]).
At present, consensus sequences in PP2A substrates have
not been identiﬁed. This review will focus on our emerging
understanding of PP2A substrate speciﬁcity, which appears
to involve additive eﬀects of multiple discrete interactions.
PP2A is a highly conserved serine/threonine phosphatase
which, depending on the tissue of origin and cell type, may
account for up to 1% of cellular protein and the majority of
serine/threoninephosphataseactivity[14].Thephysiological
f u n c t i o n so fP P 2 Ah a v eb e e ni m p l i c a t e di na l lf a c e t so f
cellularexistence(reviewedin[15]).Further,PP2Afunctions
as a critical tumor suppressor whose interruption leads to
proliferative diseases [14]. The heterotrimeric holoenzyme is
composed of a catalytic subunit (C) a scaﬀold subunit (A)
and one member of four families of regulatory subunits (B)
(Figure 1) .T h ed i v e r s i t yo fP P 2 Ah e t e r o t r i m e r si sa c h i e v e d
through expression of two C subunits, two A subunits
and approximately ﬁfteen B subunits in vertebrates. The B2 Enzyme Research
subunits are derived from four diverse gene families (B, B
,
B
,a n dB
) that have little sequence similarity between
families but maintain high sequence similarity within fam-
ilies. The B family (B55, PR55, PPP2R2) of regulatory
subunits consists of four genes (α, β, γ, δ), the B
-family
(B56, PR61, PPP2R5) is comprised of ﬁve isoforms (α,
β, γ, δ, ε), the B
 family (PR72, PPP2R3) includes three
isoforms (α/PR72/130, β/PR59, γ/PR48), and the B
 family
(PR93/PR110)ismadeupofthreeproteins(SG2NA,striatin,
and mMOB1). There is some controversy as to whether the
B
 family members, most notably SG2NA, are bona ﬁde
PP2A regulatory subunits that always associate with the AC
dimer or whether they are merely regulated by association
with the PP2A dimer. Given the large number of PP2A
subunits, it is thought that each cell expresses a dozen or
more distinct holoenzyme complexes which act on a diverse
array of substrates. PP2A holoenzyme diversity has been the
subject of several excellent papers [14, 15, 18].
Like PP1, regulatory subunit incorporation is thought
to dictate the substrate speciﬁcity of the PP2A complex,
however, only recently have molecular studies begun to
develop insight into the mechanism by which the regulatory
subunit acts [15]. The results from recent studies suggests a
multitiered mechanism wherein PP2A substrate speciﬁcity
arises from (1) subcellular localization of PP2A deﬁned
by the B subunit, (2) selective holoenzyme assembly by
posttranslational modiﬁcation, (3) interaction with speciﬁc
endogenous inhibitors, (4) interactions between the B sub-
unit and phosphosubstrates at sites distant from the active
site, and (5) B-subunit residues which inﬁltrate the catalytic
cleft of the C subunit. This paper will provide a summary of
thesestudies andhowtheunderstanding ofthedeterminants
of PP2A substrate speciﬁcity has advanced.
2. Mechanismsof SubstrateSpeciﬁcity
2.1. Subcellular Localization of the Holoenzyme Complex. The
heterotrimeric holoenzyme is targeted to discrete subcellular
locales dictated in part by which B-regulatory subunit is
incorporated. The localization imparted by the B-regulatory
subunit dictates the spatial sphere of inﬂuence of the holoen-
zyme complex for potential substrates. This mechanism of
targeting PP2A activity is highlighted by extensive studies
of the B family of regulatory subunits. For instance, the B
familyregulatorysubunitstargettheholoenzymetodiﬀerent
cellular compartments in the brain [19]. Speciﬁcally, Bα
and Bβ are primarily cytosolic where as the Bγ-regulatory
subunit associates with a detergent-resistant protein fraction
consistent with an interaction at the cytoskeleton [19].
Similar diversity has been observed in the B
 family
of regulatory subunits. A C-terminal nuclear export signal
common to B
α,B
β,a n dB
ε which, when these regulatory
subunits are incorporated into the PP2A holoenzyme, results
in cytoplasmic localization of the heterotrimer[20]. B
δ and
B
γ isoforms lack a similar sequence and are found primarily
in the nucleus [21]. In cardiomyocytes, B
α interacts with
the protein ankyrin-B through its C-terminus which leads
to localization at the cardiac M-line [22]. B
γ on the other
hand has been shown to target the holoenzyme complex
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Figure1:DiversityoftheB-regulatorysubunitsandthestructureof
the PP2A holoenzyme complex. (a) Cladogram of the human PP2A
B-regulatory subunits generated using ClustalW [16] and shown
with Dendroscope [17]. (b) Structure of the dimeric A scaﬀold
subunit and C catalytic subunit (gray). The shaded portions of
the A scaﬀold subunit indicate the known docking sites for the
B regulatory subunits; green (HEAT repeat 1) for the B family
of regulatory subunits, red (HEAT repeat 8) for the B
 family of
regulatory subunits, and yellow (HEAT repeat 2–7) for the docking
site area common for the B and B
 families. Cartoon structure of
the B (green ribbon), B
 (red ribbon), B
 (purple rectangle), and
B
 (tan circle) families of regulatory subunits. Cartoon structures
were generated using the Protein Data Bank accession codes 3DW8
and 2NPP.
to subnuclear structures in cardiomyocytes where PP2A/B
γ
m a yr e g u l a t eg e n ee x p r e s s i o n[ 23]. Loss of proper subcellular
targeting of PP2A has been implicated in the biogenesis
and aggressive phenotype of neoplastic growths. Speciﬁcally,
a truncated form of B
γ (ΔB
γ), has been isolated from a
melanoma cell line wherein the PP2A/ΔB
γ complex is tar-
geted to the trans-golgi network, blunts p53 responsiveness,
contributes to genetic instability and increases metastatic
motility [24–27].
Further complexity arises from diﬀering localization
imparted by alternative splicing of regulatory subunit genes.Enzyme Research 3
This was ﬁrst observed in a member of the B family, Bβ.
Two neuron-speciﬁc isoforms of Bβ,B β1, and Bβ2, are
generated by the use of an alternative 5 exon which results
in the production of a divergent N-terminal extension on
Bβ2[ 28, 29]. The N-terminal extension of Bβ2 directs
the holoenzyme complex to the outer mitochondrial mem-
brane (OMM) by targeting the mitochondrial translocase
complex and forming an abortive complex resistant to
import into the mitochondrial matrix [28, 30]. The OMM-
directed PP2A/Bβ2 complex promotes fragmentation of the
mitochondria reticulum and increases cell susceptibility to
proapoptotic insults through an unknown mechanism [31].
Alternative splicing of B-regulatory subunits directing sub-
cellular localization of the PP2A holoenzyme has also been
observed in both the B
 and B
 families. Two B
ε isoforms
diﬀer by the inclusion or exclusion an N-terminal nuclear
localization signal leading to isoform-speciﬁc nuclear or
cytoplasmic localization [32]. The murine-speciﬁc B
 family
member, B
δ, is also subject to alternative splicing leading to
isoform-speciﬁc nuclear or cytoplasmic localization through
an as yet unidentiﬁed mechanism [33].
Localization is also imparted by interactions between
the PP2A holoenzyme complex and other eﬀectors. For
example, the interaction between PP2A/B
 and shugoshin
during meiosis is crucial for spatial and temporal regulation
of sister chromatid disjunction. During meiosis, the cohesin
complexes, which link the arms of bivalent chromosomes
and the centromeres of sister chromatids, must be released
in a stepwise fashion by the protease separase; the cohesin
complex is ﬁrstly hydrolyzed along the arms of the bivalent
chromosomes for completion of anaphase I and secondly
at the centromeres of sister chromatids for completion of
anaphase II. During anaphase I, the centromeric cohesin
complex is protected from separase-dependent proteolysis
by shugoshin [34, 35]. Shugoshin recruits PP2A/B
 to the
centromere which likely results in dephosphorylation of
the cohesin complex leading to protection of the cohesin
complex from separase-dependent proteolysis [36, 37].
Through cocrystallization, Xu and colleagues, have revealed
that dimeric human shugoshin 1 interacts with PP2A/B
γ
through a coiled-coil region across a broad composite
surface of the C and B
γ subunits [38]. Other PP2A-eﬀector
interactions have recently been reviewed elsewhere [14].
2.2. Selective Holoenzyme Assembly and Activation. Incor-
poration of speciﬁc regulatory subunits is inﬂuenced by
reversible posttranslational modiﬁcation of the C subunit.
Many groups have shown that the C-terminus of the C sub-
unit is modiﬁed through phosphorylation and methylation
on Y307 and L309, respectively [39–46]. Phosphorylation
of Y307 is catalyzed by src kinase and is likely opposed
by PP2A-catalyzed autodephosphorylation of this phospho-
tyrosine [46]. Phosphorylation of Y307 selectively inhibits
recruitment of the B family and some B
 family members
to the dimeric AC complex whereas B
 recruitment is not
eﬀected [44].
Methylation of the C subunit at the C-terminal L309
is catalyzed by the protein phosphatase methyltransferase
(PPM1) and is opposed by the phosphatase methylesterase
(PME-1) [47–51]. Reversible methylation of PP2A is abso-
lutely critical as knocking-out PME-1 in mice changes the
phosphoproteome and results in early perinatal lethality
[52]. Further, methylation of the C subunit is a dynamic
processwhichplaysaroleincellularresponsetoacutestimuli
[53]. The recruitment of the B subunit to the AC dimer has
been postulated to require methylation of the C subunit for
some of the B-subunit families [39]. However, conﬂicting
results have been reported that may reﬂect diﬀerences in
experimental design and will be discussed further. Studies
wherein PP2A/B is isolated from intact cells have revealed
that methylation of the C subunit at L309 is required
for incorporation of the B family of regulatory subunits
into the holoenzyme complex [39, 40, 42, 44, 54, 55].
Conversely, in vitro assembly of the PP2A/B holoenzyme
complex does not require methylation of the C subunit
for incorporation of the B family of regulatory subunits
[56, 57]. Similarly controversial, the requirement for C
subunit L309 methylation was observed to be study-speciﬁc
in in vitro PP2A/B
 timer formation [58, 59]. Methylation
was dispensable for isolation of the PP2A/B
 holoenzyme
complexfromintactcells[44].Theroleofmethylationofthe
C subunit in recruitment of B
 and B
 families of regulatory
subunits is less controversial with methylation of the C
subunit being dispensable [44, 54]. For more information,
the reader is directed to an excellent recent paper [60].
Posttranslational modiﬁcations which inﬂuence forma-
tion of the PP2A holoenzyme complex also occur on the B
subunit. PP2A/B
 negatively regulates the ERK MAP kinase
signal transduction pathway [61]. Through formation of a
ternary complex of the early response gene product IEX-1,
B
γ1, and ERK, ERK mediates its own disinhibition by phos-
phorylation of B
γ1 on S327 leading to B
γ1 disassociation
f r o mt h eP P 2 Ah o l o e n z y m e[ 62]. Since S327 is conserved
among B
-subunit family members, it is likely that other
B
 subunits are regulated similarly. Additionally, Bα is likely
phosphorylated on S167 to disrupt the Bα subunit from the
AC dimer in early mitotic stages. However, PP2A/Bα activity
is necessary to resolve the mitotic spindles and conclude
mitosis; therefore, autodephosphorylation may occur on Bα
to allow eﬃcient PP2A/Bα heterotrimer formation and cell
cycle progression [63]. Thus, phosphorylation of the B-
regulatory subunits also inﬂuences holoenzyme assembly
and, therefore, substrate speciﬁcity.
PhosphorylationoftheBsubunitofheterotrimericPP2A
also potentiates the catalytic activity of the holoenzyme
complex.InresponsetoactivationofD1dopamine receptors
on striatal neurons, cAMP-dependent protein kinase A
(PKA) phosphorylates B
δ at S566 increasing activity of
the PP2A/ B
δ holoenzyme towards dopamine- and cAMP-
regulated neuronal phosphoprotein (DARPP-32)[ 64, 65].
Dephosphorylation of T75 on DARPP-32 by PP2A/B
δ
disinhibits PKA-mediated phosphorylation of DARPP-32 at
T34 which converts DARPP-32 into a potent PP1 inhibitor
leading to changes in neuronal signaling. This circuit acts to
attenuatephospho-T75inhibitionofT34phosphorylationof
DARPP-32. This circuit has been shown to be diﬀerentially
regulated by psychomotor stimulants and antipsychotics
acting on diﬀerent striatal neuron subpopulations [66].4 Enzyme Research
Bα 142 DFDPEEDEPTL
Bβ 148 EFDPEEDEPNL
Bγ 117 EFDPEEDEPTL
Bδ 193 EFDPEEDEPTL
Bε 134 EFDPEEDEPTL
(a)
Bγ 78 PEFDYLKSLEIEE
Bδ 88 PEFDYLKSLEIEE
Bα 82 PEFDYLKSLEIEE
Bβ28 1 PEFDYLKSLEIEE
(b)
Figure 2: A portion of the B
-and B-regulatory subunits contacts the active site of the C-catalytic subunit. Ribbon diagrams showing a
“top-down” view of two heterotrimeric holoenzyme PP2A complexes. The subunits of the holoenzyme complexes are color-coded with the
catalytic C subunit in gray, the scaﬀold A subunit in yellow, and B subunits in blue. The PP2A inhibitor microcystin-LR is shown near the
active site as a red stick ﬁgure. (a), Structure of the PP2A/B
γ holoenzyme (PDB 2NPP); inset highlights the inﬁltration of the B
γ-subunit
residue, E122 (green), into the catalytic core above. Below, sequence alignment of the B
 family of regulatory subunits with the conserved
glutamate residue (green). (b), Structure of the PP2A/Bα holoenzyme (PDB 3DW8); inset shows inﬁltration of the Bα-subunit residues, K88
(green), into the catalytic core above. Below, sequence alignment of the B family of regulatory subunits with the conserved lysine residue
(green).
2.3. Regulating PP2A through Protein Inhibitors. While
assembly of the many trimeric PP2A holoenzymes directs
cellular localization and substrate speciﬁcity, further reg-
ulation is aﬀorded through binding of speciﬁc protein
inhibitors of PP2A. One such inhibitor SET (I2/TAF-1) is
upregulated during the progression of chronic myelogenous
leukemia through BCR/ABL activity and results in decreased
PP2A activity. Importantly, restoring PP2A activity prevents
disease progression in an animal model of leukemogenesis
[67]. An additional PP2A inhibitor is the protein CIP2A
(cancerous inhibitor of PP2A), overexpression of which is
associated with several human malignancies. CIP2A asso-
ciates with c-myc to protect its phosphorylated S62 from
PP2A-directed activity stabilizing the c-myc protein and
allowing it to promote oncogenesis [68].
Recently an interplay between the Drosophila serine/
threonine kinase Greatwall (gwl) and PP2A/Bδ was observed
during mitotic entry in two separate studies [69, 70].
PP2A/Bδ activity prevents mitotic entry by maintaining
Cdc25 in a dephosphorylated and inactive state. Gwl reverses
this inhibition through the phosphorylation of S67 of both
α-endosulﬁne (Ensa) and cyclic adenosine monophosphate-
(cAMP-) regulated phosphoprotein-19 (Arpp-19). Phos-
phorylation converts Ensa and Arpp-19 into very speciﬁc
inhibitors of PP2A/Bδ activity and produces activation of
Cdc25 leading to cell cycle progression. Similar cell cycle
regulatory activity has been observed with the mammalian
ortholog of gwl, MASTL; however, the MASTL-PP2A inter-
action has yet to be characterized [71].
2.4. Substrate Recruitment by Regulatory Subunit Interactions
Distant from the Active Site. Once targeted to speciﬁc subcel-
lularlocales,thePP2Aholoenzymemustrecruitanddephos-
phorylate target substrates. Recent structural studies have
begun to suggest the mechanism by which the regulatory
subunit of PP2A mediates initial binding to target substrates.Enzyme Research 5
The B family of regulatory subunits adopts a seven-bladed
β-propeller structure [72]. Other β-propeller proteins have
been shown to bind ligands in the central depression on the
top surface of the toroid [73]. Crystallization of PP2A/Bα
revealed a cluster of acidic residues in this depression that
is available to recruit potential substrates containing a basic
motif[56].Inthissamestudy,theacidiccentraldepressionof
Bα was experimentally conﬁrmed to bind the microtubule-
associated protein tau, an established PP2A/Bα substrate.
Several conserved aspartate and glutamate residues in Bα
engage in weak, electrostatic interactions across a large basic
portion of tau and support dephosphorylation of tau at
multiple sites through cycles of binding and unbinding [56].
Structurally divergent B
 family members may recruit
substrates in a similar fashion as the B family. The crystal
structure of PP2A/B
γ shows that the B
 subunit contains
18 stacked α-helices which adopt 8 huntingtin elongation
A subunit Tor- (HEAT-) like repeats [58, 59]. A portion
of these HEAT-like repeats interact with the A subunit of
theholoenzymetomediateregulatorysubunitincorporation
into the holoenzyme complex. Like the Bα subunit, an acidic
patch is exposed in the B
 family of regulatory subunits
and may mediate protein-protein interactions and substrate
recruitment [59].
2.5. Substrate Recruitment by Regulatory Subunit Interactions
N eartheA ctiveSite. StructuralstudiesofPP2Ahaverevealed
a conserved loop in the B
 family of regulatory subunits
whichinﬁltratesthecatalyticcoreoftheholoenzyme[58,59]
(Figure 2(a)). At the tip of this loop is a conserved glutamate
residue, E153 (B
β numbering), which contacts through
its carbonyl oxygen the catalytic subunit and through its
carboxyl group a cocrystallized microcystin molecule in
the active site. Mutational analysis revealed that E153 is
an absolute requirement for eﬃcient dephosphorylation of
tyrosine hydroxylase (TH), a known PP2A/B
β substrate, as
well as other as yet unidentiﬁed cellular substrates of this
PP2Aholoenzyme[74].Further,itwasdeterminedthatE153
of B
β interacts with R37 and R38 of TH to mediate dephos-
phorylation of both S31 and S40 on TH. Positively charged
residues in the vicinity of target phospho-serine/threonine
residues could represent a consensus sequence for B
-
subunit-mediated dephosphorylation. Further, the inﬁltrat-
ingloopislikelyaconformationallydynamicstructurewhich
is not sterically hindered by surrounding portions of the A,
C, or B subunits. Since R37/38 are important for dephos-
phorylation of both upstream (S40) and downstream (S31)
sites, it appears that the orientation of phosphopeptides
relative to the catalytic cleft is not constrained by additional
interactions. Collectively, the above observations support a
model in which the sites of interaction between the substrate
and the B regulatory subunit that are distant and near the
active site together control substrate speciﬁcity. First, the
interaction occurring at sites distant from the active site
increases the local substrate concentration. Following this
initial substrate recruitment, the interactions near the active
site mediate site-speciﬁc dephosphorylation.
Although divergent in its sequence, an analogous struc-
ture from the β-propeller fold of the B family of regulatory
subunits extends to the catalytic core of the holoenzyme
[56]( Figure 2(b)). This loop places conserved residues of
the B-family subunits very near the holoenzyme active site.
Unpublished observations generated in our lab suggests that
of these loop residues K87 of Bβ2 may play a similar role
as E153 of B
β in site-speciﬁc dephosphorylation of target
substrates;however,furthercharacterizationofthissubstrate
speciﬁcity loop is required.
3. Conclusion
PP2A is a ubiquitous protein phosphatase responsible for the
dephosphorylation of many diﬀerent intracellular targets.
The diverse repertoire of potential substrates for PP2A is
imparted by the incorporation of one of ﬁfteen unique
B-regulatory subunits. Recent studies have increased our
understanding of the mechanisms by which the B subunit
imparts speciﬁcity to the holoenzyme complex. Through
selective incorporation of the B-regulatory subunit, the
holoenzyme complex is recruited to discrete subcellu-
lar locales which deﬁne the sphere of inﬂuence for the
phosphatase. Secondly, interactions between endogenous
inhibitors and speciﬁc PP2A heterotrimers further restrict
phosphatase activity. As shown for the B family, regulatory
subunits mediate low-aﬃnity interactions with substrates to
increase the local concentration of substrates. Through a
ﬂexible substrate selectivity loop which contacts the catalytic
subunit, interactions between the regulatory subunit and
phosphosubstrate may mediate multiple nearby dephospho-
rylation events. With the current structural information
available for the PP2A complexes, future high-resolution
studies will further deﬁne the molecular mechanism of
PP2A substrate speciﬁcity. As general, inhibitors of PP2A
are either clinically irrelevant or toxic, as in the case of
the small molecule inhibitor microcystin, novel methods
to increase the speciﬁcity of PP2A inhibition or activation
must be developed. A clearer understanding of the PP2A
substrate speciﬁcity mechanisms will serve as the foundation
for rational drug design of selective inhibitors and activators
of speciﬁc PP2A holoenzyme complexes.
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